On March 13, 2012 a German judge provided a ruling dismissing a CoQ10 patent infringement case previously brought by Kaneka against Zhejiang Medicine Company and its European Distributor, Kyowa Hakko GmbH Europe (“KHE”). On November 11, 2010 Kaneka Corporation initiated legal proceedings in Germany against Zhejiang Medicine Company ("ZMC") and KHE alleging infringement of its patent relating to Coenzyme Q10. After an inspection held at the ZMC facilities March 3, 2012, the judge in the case dismissed the case brought by Kaneka against ZMC as unfounded and lacking of infringement. Kaneka Corporation is also found to be liable for all litigation costs accrued by both ZMC and KHE in the case based on a ruling handed down March 13, 2012 in Dusseldorf, Germany.
Jiang Xiao Yue, CEO, ZMC, stated “while we are happy with the outcome of the judge’s decision in this case we are not surprised. ZMC has contended from the beginning of these lawsuits, the allegations presented are baseless and have been largely motivated by short term market manipulation rather than true legal content.” Mr. Jiang went on to say “ZMC is confident the outcome of the many similar lawsuits filed by Kaneka Corporation around the globe against ZMC will be found to be equally without foundation or merit.”
ABOUT: Zhejiang Medicine Company (ZMC) is an active ingredient manufacturer offering high quality
pharmaceutical and nutraceutical ingredients improving the lives of the world's consumers since 1954.
ZMC is staffed with over 4,000 employees globally and is an important production base of
pharmaceutical drugs, Biotin, Vitamin A, Astaxanthin, Natural and Synthetic Vitamin E, Patented Lutein,
Phytosterol, B-Carotene, Zeaxanthin, Patented Lycopene, and Coenzyme Q10. ZMC operates in North
America as ZMC-USA from its office in The Woodlands, Texas. www.zmc-usa.com